
Setmelanotide shows efficacy at phase 3 for POMC and LEPR deficiency obesity
The melanocortin 4 receptor agonist setmelanotide has significantly reduced hunger and resulted in weight loss in a phase 3 trial involving patients, including children, with pro-opiomelanocortin or leptin receptor deficiency obesity.